Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial

Agnieszka Wierzbowska, MD PhD, Ewa Wawrzyniak, PhD, Agnieszka Pluta, MD PhD, Tadeusz Robak, MD PhD, Grzegorz J. Mazur, MD PhD, Anna Dmoszynska, MD PhD, Jaroslav Cermak, MD PhD, Albert Oriol, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 1336.

https://doi.org/10.1182/blood.V126.23.1336.1336

Published: 2015

Journal Articles

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

Robert Z. Orlowski, MD, PhD, Arnon Nagler, MD, Pieter Sonneveld, MDPhD, Joan Bladé, MD PhD, Roman Hajek, Andrew Spencer, MD, Tadeusz Robak, MD, Anna Dmoszynska, Noemi Horvath, MB,ChB, FRACP, FRCPA, Ivan Spicka, Heather J. Sutherland, MD PhD FRCPC, Alexander Suvorov, MD, Liang Xiu, Trilok V. Parekh, PhD, Jesús San Miguel, MD

Blood (2014) 124 (21): 3448.

https://doi.org/10.1182/blood.V124.21.3448.3448

Published: 2014

Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood (2014) 124 (3): 420–425.

https://doi.org/10.1182/blood-2013-12-538975

Published: 2014

Includes: Supplemental data

Journal Articles

Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells

Krzysztof Giannopoulos, MD, PhD, Joanna Zaleska, Katarzyna Skorka, Malgorzata Zajac, Agnieszka Piechnik, Marta Karp, Maciej Grzywnowicz, Waldemar Tomczak, Paulina Wlasiuk, Anna Dmoszynska

Blood (2013) 122 (21): 2859.

https://doi.org/10.1182/blood.V122.21.2859.2859

Published: 2013

Journal Articles

In Chronic Lymphocytic Leukemia PD-1 Is Expressed Independently From PDCD1 Gene Polymorphisms and Does Not Influence BCR Signaling

Krzysztof Giannopoulos, MD, PhD, Maciej Grzywnowicz, Lidia Karabon, PhD, Agnieszka Piechnik, Malgorzata Zajac, Katarzyna Skorka, Joanna Zaleska, Waldemar Tomczak, Paulina Wlasiuk, Irena Frydecka, MD, PhD, Anna Dmoszynska

Blood (2013) 122 (21): 1625.

https://doi.org/10.1182/blood.V122.21.1625.1625

Published: 2013

Journal Articles

CD1d Expression Is Higher In Chronic Lymphocytic Leukemia Patients With Unfavorable Prognosis

Agnieszka Bojarska-Junak, Iwona Hus, Anna Dmoszynska, Jacek Rolinski

Blood (2013) 122 (21): 5278.

https://doi.org/10.1182/blood.V122.21.5278.5278

Published: 2013

Journal Articles

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

Lidia Usnarska-Zubkiewicz, Jakub Debski, MD, Aleksandra K. Butrym, MD, PhD, Wojciech Legiec, Marek Hus, MD, PhD, Anna Dmoszynska, Beata Stella-Holowiecka, MD, Jan M Zaucha, Marcin Rymko, MD, Tigran Torosian, MD, Grzegorz Charlinski, Ewa Lech-Maranda, Artur J. Jurczyszyn, MD, PhD, Halina Urbanska-Rys, Agnieszka Druzd-Sitek, PhD, Kazimierz Kuliczkowski

Blood (2013) 122 (21): 3236.

https://doi.org/10.1182/blood.V122.21.3236.3236

Published: 2013

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

Bendamustine in Monotherapy and in Combination Regimens in the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma – a Retrospective Analysis

Iwona Hus, Dariusz Jawniak, Magdalena Gorska-Kosicka, Aleksandra Butrym, Justyna Dzietczenia, Tomasz Wrobel, Grzegorz Mazur, MD, PhD, Ewa Lech-Maranda, Krzysztof Warzocha, MD, PhD, Anna Waszczuk-Gajda, Wieslaw Wiktor-Jedrzejczak, MD, PhD, Malgorzata Krawczyk-Kulis, Slawomira Kyrcz-Krzemien, MD PhD Prof, Lidia Poplawska, Jan Walewski, Anna Dmoszynska

Blood (2012) 120 (21): 4602.

https://doi.org/10.1182/blood.V120.21.4602.4602

Published: 2012

Journal Articles

Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens

Norbert Grzasko, MD, PhD, Marek Hus, MD, PhD, Marta Morawska, MD, PhD, Roman Hajek, MD, PhD, Anna Dmoszynska

Blood (2011) 118 (21): 2874.

https://doi.org/10.1182/blood.V118.21.2874.2874

Published: 2011

Journal Articles

Efficacy and Safety of Biosimilar G-CSF and Originator G-CSF for Haematopoietic Stem Cell Mobilisation: A Randomised Comparison

Anna Dmoszynska, Joanna Manko, MD, Adam Walter Croneck, MD, Norbert Grzasko, MD, Piotr Klimek, MD, Aleksandra Nowaczynska, MD, Magdalena Gorska-Kosicka, MD

Blood (2011) 118 (21): 4392.

https://doi.org/10.1182/blood.V118.21.4392.4392

Published: 2011

Journal Articles

Use of Biosimilar G-CSF Is Effective After Autologous Bone Marrow Transplantation

Katarzyna Kotwica, MD, Maria B. Cioch, MD, Malgorzata Wach, MD, PhD, Joanna Manko, MD, Dariusz Jawniak, MD, Adam Walter-Croneck, MD, Wojciech Legiec, MD, Anna Dmoszynska

Blood (2011) 118 (21): 5321.

https://doi.org/10.1182/blood.V118.21.5321.5321

Published: 2011

Journal Articles

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma (MM) Patients: a Preliminary Report of Polish Myeloma Group

Lidia Usnarska-Zubkiewicz, MD, Jakub Debski, MD, Aleksandra Butrym, MD, Wojciech Legiec, MD, Anna Dmoszynska, Beata Stella-Holowiecka, MD, Jan Maciej Zaucha, MD, Marcin Rymko, MD, Tigran Torosian, MD, Kazimierz Kuliczkowski

Blood (2011) 118 (21): 5125.

https://doi.org/10.1182/blood.V118.21.5125.5125

Published: 2011

Journal Articles

Th17/IL-17 Might Play a Protective Role in CLL Immunity

Iwona Hus, Jacek M. Rolinski, Agnieszka ABJ Bojarska-Junak, Magdalena Gorska, Anna Dmoszynska

Blood (2011) 118 (21): 2843.

https://doi.org/10.1182/blood.V118.21.2843.2843

Published: 2011

Journal Articles

Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia

Krzysztof Giannopoulos, MD, PhD, Marcin Omiotek, Kamila Kosior, Radoslaw Mlak, Malgorzata Kowal, Jacek M. Rolinski, Hartmut Dohner, MD, Stephan Stilgenbauer, MD, Anna Dmoszynska, Lars Bullinger

Blood (2011) 118 (21): 4608.

https://doi.org/10.1182/blood.V118.21.4608.4608

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,

Blood (2011) 118 (21): 3915.

https://doi.org/10.1182/blood.V118.21.3915.3915

Published: 2011

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Is Type of Monosomy (Total or Partial) Crucial for Prognostic Value of Monosomal Karyotype in AML Patients? – Preliminary Results of Retrospective Polish Adult Leukemia Group (PALG) Study,

Blood (2011) 118 (21): 3537.

https://doi.org/10.1182/blood.V118.21.3537.3537

Published: 2011

NARROW

Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells

In Chronic Lymphocytic Leukemia PD-1 Is Expressed Independently From PDCD1 Gene Polymorphisms and Does Not Influence BCR Signaling

CD1d Expression Is Higher In Chronic Lymphocytic Leukemia Patients With Unfavorable Prognosis

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Bendamustine in Monotherapy and in Combination Regimens in the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma – a Retrospective Analysis

Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens

Efficacy and Safety of Biosimilar G-CSF and Originator G-CSF for Haematopoietic Stem Cell Mobilisation: A Randomised Comparison

Use of Biosimilar G-CSF Is Effective After Autologous Bone Marrow Transplantation

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma (MM) Patients: a Preliminary Report of Polish Myeloma Group

Th17/IL-17 Might Play a Protective Role in CLL Immunity

Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Is Type of Monosomy (Total or Partial) Crucial for Prognostic Value of Monosomal Karyotype in AML Patients? – Preliminary Results of Retrospective Polish Adult Leukemia Group (PALG) Study,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only